LIESTAL, Switzerland--(BUSINESS WIRE)--Curatis Holding (SIX:CURN) has explored in detail which regulatory pathway should be pursued in view of a possible approval of C-PBTE-01 in the USA. The detailed clarifications in collaboration with a renowned US law firm and their regulatory experts have shown that C-PTBE-01 meets the criteria for a Biologic License Application (BLA). If approved in the USA, this would result in a market protection of 12 years, significantly longer than the 7 years market protection under orphan drug status. This would extend the market protection for C-PTBE-01 in the USA by 70% or 5 years.
According to the US Public Health Service Act, the status of “biologic” is intended for peptides with a length of more than 40 amino acids. The molecule C-PTBE-01 has a length of 41 amino acids. The orphan drug designation for C-PTBE-01 will be pursued as planned.
About C-PTBE-01
Curatis is focusing its development activities for C-PTBE-01 on an very rare group of aggressive brain tumours (Diffuse Midline Glioma, DMG). These tumours mainly affect children, with most cases being diagnosed between the ages of 5 and 9. In the USA, around 800 patients are diagnosed with DMG every year; in Europe, the number is in the same order of magnitude, which is why the disease is considered a ‘rare disease’ for regulatory purposes.
In connection with DMG, indirect brain damage regularly occurs due to an accumulation of extracellular fluid in the vicinity of the tumour. This peritumoural brain edema (PTBE) can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status and can be life-threatening.
The current typical treatment method for PTBE is the use of corticosteroids. Corticosteroids often have serious side effects such as severe myopathies, muscle wasting, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. The already serious side effects are exacerbated in children.
C-PTBE-01 has demonstrated a strong steroid-sparing effect in two clinical safety and efficacy studies, which may lead to a significant reduction or complete replacement of corticosteroid use and thus alleviation of the severe side effects associated with steroid use in children.
A detailed analysis of Curatis and its product candidates is available in a research report at https://ir.curatis.com/equity-research-reports.
About Curatis:
Curatis Holding AG is a publicly listed company (CURN.SW) specialising in the development and commercialisation of drugs for rare and very rare diseases. Curatis has a sales portfolio of more than 30 drugs and a pipeline of orphan drug products and speciality products that can make a significant contribution to cash flow from 2025 onwards. Further information can be found on the website www.curatis.com.
Disclaimer:
The information contained in this media release and in any link to our website indicated here is not for use in any country or jurisdiction or by any persons where such use would constitute a violation of law.
This media release contains "forward-looking statements" that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words "may", "will", "should", "continue", "believe", "anticipate", "expect", "estimate", "intend", "project", "plan", "will likely continue", "will likely result", or words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside the control of Curatis Group, that may cause Curatis' business, strategy or actual results to differ materially from the forward-looking statements (or from past results). For any factors that could cause actual results to differ materially from the forward-looking statements contained in this media release, please see our listing prospectus in connection with the business combination from April 2024. Curatis Group undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance.
The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act nor a prospectus under any other applicable laws.
Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this media release may slightly vary from the exact arithmetic aggregation of the figures that precede them.
